Literature DB >> 17786283

Effect of scopoletin on lipoprotein lipase activity in 3T3-L1 adipocytes.

Jeong-Yeh Yang1, Jeung-Hyun Koo, Ha-Yong Yoon, Ju-Hyung Lee, Byung-Hyun Park, Jong-Suk Kim, Myung S Chi, Jin-Woo Park.   

Abstract

Hypertriglyceridemia is an independent risk factor of cardiovascular diseases. It is caused by the imbalance between hepatic triglyceride production and peripheral removal. Lipoprotein lipase (LPL) plays a central role in the removal of plasma triglyceride. During the screening of possible anti-dyslipidemic drugs, we observed that scopoletin (6-methoxy-7-hydroxycoumarin) significantly increased LPL activity in adipocytes. Scopoletin increased LPL activity in culture medium of 3T3-L1 adipocytes in dose- and time-dependent manners. It did not release LPL from the adipocyte membrane and, instead, increased the LPL mRNA level, suggesting transcriptional control. Scopoletin also partially reversed tumor necrosis factor-alpha-induced suppression of LPL activity. These results suggest the possible action of scopoletin as a facilitator of plasma triglyceride clearance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17786283

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  3 in total

Review 1.  Molecular mechanism of down-regulating adipogenic transcription factors in 3T3-L1 adipocyte cells by bioactive anti-adipogenic compounds.

Authors:  Ajay Guru; Praveen Kumar Issac; Manikandan Velayutham; N T Saraswathi; Aziz Arshad; Jesu Arockiaraj
Journal:  Mol Biol Rep       Date:  2020-12-04       Impact factor: 2.316

Review 2.  Urtica spp.: Ordinary Plants with Extraordinary Properties.

Authors:  Dorota Kregiel; Ewelina Pawlikowska; Hubert Antolak
Journal:  Molecules       Date:  2018-07-09       Impact factor: 4.411

Review 3.  Artemisia scoparia and Metabolic Health: Untapped Potential of an Ancient Remedy for Modern Use.

Authors:  Anik Boudreau; Allison J Richard; Innocence Harvey; Jacqueline M Stephens
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-08       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.